Research programme: gamma interferon based therapeutics - A5 laboratories

Drug Profile

Research programme: gamma interferon based therapeutics - A5 laboratories

Alternative Names: VI-1718

Latest Information Update: 11 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator A5 Laboratories
  • Class Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer; Multiple sclerosis; Viral infections

Most Recent Events

  • 11 Mar 2011 Preclinical development is ongoing in Canada
  • 28 Jul 2010 Preclinical trials in Cancer in Canada (unspecified route)
  • 28 Jul 2010 Preclinical trials in Multiple sclerosis in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top